Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy

Hsu, Jen-Yu; Sun, Hsin‐Yun; Hsieh, Tan-Wen; Chang, Sui‐Yuan; Chuang, Yu‐Chung; Huang, Yu‐Shan; Hsiao, Ching Hua; Su, Yi‐Ching; Liu, Wen-Chun; Chang, Shu-Fang; Hung, Chien‐Ching

doi:10.1016/j.jgar.2022.02.007

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More studies on using INSTIs in LLV patients are needed to generate more evidence‐based data. A total of 1078 PLWH were included, and the incidence rates of LLV and VF after the switch to co‐formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/c/FTC/TAF) were 3.5 and 0.8 events per 100 person‐years of follow‐up (PYFU), respectively, whereas the respective cumulative incidence of LLV and VF reached 11.7% and 2.9% within 3 years of follow‐up [60]. LLV was associated with any LLV episode before or after the switch and prior exposure to INSTIs‐based ART.…”

Section: Impact Of Instis On Llvmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors

Shi,

Ying,

Zheng

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

BackgroundPeople living with HIV (PLWH) and receiving antiretroviral therapy (ART) have a goal of achieving and maintaining viral suppression; however, the existence of PLWH that show events of low‐level viremia (LLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. Moreover, some reports indicate that LLV status can lead to residual immune activation and inflammation, leading to a higher occurrence of non‐AIDS‐defining events (nADEs) and other adverse clinical outcomes. Until now, however, published data have shown controversial results that hinder understanding of this phenomenon's actual cause(s) and origin(s). Integrase strand transfer inhibitors (INSTIs)‐based therapies could lead to lower LLV over time and, therefore, more effective virological control.ObjectivesThis review aims to assess recent findings to provide a view of the clinical significance and management of low‐level HIV viremia in the era of INSTIs.

show abstract

Section: Impact Of Instis On Llvmentioning

confidence: 99%

“…VF was associated with any LLV before or after the switch and prior exposure to raltegravir, but not the level or frequency of LLV. The risks of LLV and VF were low in PLWH who had achieved VS and switched to EVG/c/FTC/TAF [60].…”

Section: Impact Of Instis On Llvmentioning

confidence: 99%